The Texas Pharmacy Association (TPA) has received a grant from the Community Pharmacy Foundation and Texas Department of State Health Services that will allow the association to create community-based health care provider digital linkages with pharmacists. Read More »
The Centers for Medicare and Medicaid Services recently authorized Texas-based McKesson Specialty Health as a Qualified Clinical Data Registry, rendering it eligible to participate in the Merit-Based Incentive Payment System for 2017. Read More »
Fortified with time-release traits, Egalet Corp.’s Guardian tablet has received a U.S. patent, enabling the Pennsylvania-based firm to adapt the medication for potential future products. Read More »
Mutual recommitment to a partnership between Pfizer and two U.S. foundations has successfully ensured continued access to Pfizer’s Sayana Press contraceptive for women in the world’s poorest nations. Read More »
A pioneering prototype blending a mood stabilizer with technology is on the radar for two companies determined to develop a combination drug/device that, if approved by the FDA, could potentially address serious mental health challenges. Read More »
With kidney disease ranking in the nation’s top 10 causes of death, Sanofi recently announced a breakthrough with FDA approval of its branded Thymoglobulin for boosting immunosuppression for patients to prevent rejection following kidney transplants. Read More »
Pfizer Inc. and Celltrion Healthcare presented data at the 12th Congress of the European Chron’s and Colitis Organisation showing Inflectra (infliximab CT-P13) delivers similar efficacy and safety as Remicade (infliximab) for treating Chron’s Disease. Read More »
AstraZeneca and TerSera Therapeutics LLC (TerSera) have entered a agreement that gives TerSera the commercial rights to Zoladex in the United States and Canada. Read More »
Pfizer Inc. recently shared positive data from its Phase 2 study examining Clostridium difficile (C. difficile) vaccine candidate, PF-06425090, a product created to help prevent C. difficile infection (CDI), which can include life-threatening diarrhea and pseudomembranous colitis. Read More »
Pfizer Inc. recently announced that its Xeljanz drug for treating moderate to severe active rheumatoid arthritis (RA) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Read More »
A Nevada bill headed to the desk of Governor Brian Sandoval (R) would do nothing to decrease prescription drug costs, according to the Council of Citizens Against Government Waste (CCAGW). Read More »
Panacea Pharmaceuticals has filed a U.S. patent application for Immune System Enhancing Immunotherapy for the treatment of cancer. Read More »
Endo International plc recently announced that one of its operating companies, Endo Pharmaceuticals Inc. based in Malvern, Pennsylvania, is voluntarily recalling one lot of Edex (alprostadil) for injection because the company detected a defect in the crimp caps used in the manufacture of the subject product lot. Read More »
DelMar Pharmaceuticals recently hosted a Key Opinion Leader forum at the Lotte New York Palace Hotel in New York City, highlighting its novel treatment for patients suffering from glioblastoma multiforme. Read More »
Six finalists of the Sandoz HACk presented their ideals to a panel of judges at WIRE Health in London. Read More »
Sanofi and Regeneron Pharmaceuticals Inc. recently shared the results of a Phase 3 Chronos study as a late-breaking abstract at the annual meeting of the American Academy of Dermatology. Read More »
CVS Health recently released a report highlighting the health care needs of an aging population, noting that Americans are living longer than ever before. Read More »
GSK has submitted a supplemental Biologics License Application for Fluarix Quadrivalent (influenza vaccine) to the U.S. Food and Drug Administration. Read More »
Pfizer Inc. and EMD Serono, Merck KHaA’s biopharmaceutical arm in the United States and Canada, recently announced that Bavencio was approved by the Food and Drug Administration for intravenous use. Read More »
Portola Pharmaceuticals Inc. presented data from its pivotal Phase 3 APEX study for the investigational drug betrixaban at a poster session at the American College of Cardiology’s 66th Annual Scientific Session & Expo. Read More »
Alerts Sign-up
